-
Mashup Score: 0
– Companies plan to discuss results with regulatory authorities – TOKYO and BOTHELL, Wash., July 26, 2022 /PRNewswire/ — Astellas Pharma Inc. (ALPMF) (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seagen Inc. (SGEN) today announced positive topline results from the phase 1b/2 EV-103 clinical trial (also known as KEYNOTE-869) Cohort K evaluating PADCEV® (enfortumab…
Source: SeekingAlphaCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2Drug pricing legislation will affect biopharma revenue, but impact is manageable - RBC - 2 year(s) ago
Proposed drug pricing legislation from Senate Democrats, if passed, would have an impact on revenue for pharmaceutical and biotech companies, but the influence would not be that significant
Source: SeekingAlphaCategories: Healthcare Professionals, Latest HeadlinesTweet-
Drug pricing legislation will affect biopharma revenue, but impact is manageable - RBC | Seeking Alpha https://t.co/1FgMBW740s
-
-
Mashup Score: 2
Barclays (BCS) is expected to buy a stake in Copper, a cryptocurrency-focused firm providing custody services to institutional investors, according to a report by Sky News released…
Source: SeekingAlphaCategories: Healthcare Professionals, Latest HeadlinesTweet-
RT @bitcoinagile: Barclays said to take stake in cryptocurrency custodian Copper NYSE:BCS https://t.co/8HNheH3jFj https://t.co/U2ecWjga0j
-
-
Mashup Score: 0Novavax shares plunge 23% amid severe allergic reactions risk with COVID vaccine (NVAX) - 2 year(s) ago
Novavax (NVAX) shares have plunged 23% in Thursday afternoon trading after the European Medicines Agency said that severe allergic reactions will be added as a potential side effect for…
Source: SeekingAlphaCategories: Healthcare Professionals, Latest HeadlinesTweet-
$NVAX - Novavax shares plunge 23% amid severe allergic reactions risk with COVID vaccine https://t.co/zjFE87u36X
-
-
Mashup Score: 116Composition of next COVID boosters raises questions (NYSE:PFE) - 2 year(s) ago
The FDA guidance on updating the next COVID-19 shots for the fall booster campaign has prompted some experts to doubt their likely immune response, while some even question the need…
Source: SeekingAlphaCategories: Latest Headlines, PediatricsTweet-
Composition of next COVID boosters raises questions (NYSE:PFE) | My comments @SeekingAlpha https://t.co/jKt3Dir2k2
-
-
Mashup Score: 6
Commercial-stage biotech BioMarin Pharmaceutical (BMRN) announced on Tuesday that the FDA requested additional data for its planned Biologics Licensing Application ((BLA)) for hemophilia…
Source: SeekingAlphaCategories: Hem/Oncs, Latest HeadlinesTweet-
There will be a 3 month delay before Biomarin reapply for approval of their #hemophilia A gene therapy, ValRox or Roctavian. Apparently the FDA has asked for additional data analysis. So the earliest this will be approved is 2023. https://t.co/Sgnm1oebF1
-
-
Mashup Score: 1Microsoft: Nadella's $5 Billion Bet On IoT To Pay Off (MSFT) - 3 year(s) ago
In 2018, Microsoft pledged to invest $5 billion in the IoT. See why I believe IoT is one of MSFT’s most promising growth opportunities over the next decade.
Source: SeekingAlphaCategories: Healthcare Professionals, Latest HeadlinesTweet-
$MSFT - Microsoft: Satya Nadella's $5 Billion Bet On #IoT Is Starting To Pay Off. https://t.co/Ra75eLmcA7 https://t.co/IQAITbZOVP
-
-
Mashup Score: 0Bristol Myers' Opdivo/Yervoy fails to improve survival in bladder cancer patients in trial - 3 year(s) ago
Bristol Myers Squibb’s (BMY) late-stage study of Opdivo plus Yervoy as a first-line therapy, did not meet the main goal of overall survival ((OS)) in certain patients with…
Source: SeekingAlphaCategories: Latest Headlines, Oncologists2Tweet-
Tough times for immunotherapy in bladder cancer… “Bristol Myers' Opdivo/Yervoy combo fails to improve overall survival in certain bladder cancer patients in trial” https://t.co/v1Idakx8Mn
-
-
Mashup Score: 0
Zoom Video Communications (ZM) has agreed to acquire Solvvy as part of its plan to drive contact center expansion.Financial terms of the deal were not disclosed.Solvvy is a…
Source: SeekingAlphaCategories: Healthcare Professionals, Latest HeadlinesTweet-
Zoom agrees to acquire AI customer service platform Solvvy https://t.co/hrB72oFkq0
-
-
Mashup Score: 2Teladoc is down 78% over the last year. Can it recover as COVID concerns subside? (TDOC) - 3 year(s) ago
During the height of the COVID-19 pandemic, Teladoc Health (TDOC) was one of the most successful stocks, benefitting from a move to medical care virtually rather than in a…
Source: SeekingAlphaCategories: Healthcare Professionals, Latest HeadlinesTweet-
Teladoc is down 78% over the last year. Can it recover as COVID concerns subside? https://t.co/HkOYaS7CVG
-
Astellas and Seagen Announce Positive Topline Results For PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as First-Line Treatment for Advanced Urothelial Cancer https://t.co/eIiuLVE6bC